Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
-0.02 (-1.25%)
Real-time:   1:21PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.52 - 1.64
52 week 1.38 - 3.18
Open 1.62
Vol / Avg. 975,491.00/1.66M
Mkt cap 811.79M
P/E     -
Div/yield     -
EPS -0.20
Shares 513.79M
Beta 2.03
Inst. own 92%
May 5, 2014
Q1 2014 Lexicon Pharmaceuticals Inc. Earnings Release (Estimated) Add to calendar
Apr 24, 2014
Lexicon Pharmaceuticals Inc. Annual Shareholder Meeting
Apr 14, 2014
Lexicon Pharmaceuticals Inc. to Discuss the LX4211 Phase 2 Type 1 Clinical Trial Conference Call
Apr 8, 2014
Lexicon Pharmaceuticals Inc. at Needham Healthcare Conference
Mar 5, 2014
Lexicon Pharmaceuticals Inc. at Cowen Health Care Conference
Feb 28, 2014
Q4 2013 Lexicon Pharmaceuticals Inc. Earnings Conference Call
Feb 28, 2014
Q4 2013 Lexicon Pharmaceuticals Inc. Earnings Release
Feb 10, 2014
Lexicon Pharmaceuticals Inc. at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1235.04% -4686.14%
Operating margin -1203.97% -4607.16%
EBITD margin - -4478.31%
Return on average assets -24.35% -32.24%
Return on average equity -39.25% -47.67%
Employees 230 -
CDP Score - -


8800 Technology Forest Place
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211, LX1032, LX1033, LX2931 and LX7101.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Arthur T. Sands M.D., Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate Development
Age: 48
Bio & Compensation  - Reuters
Brian P. Zambrowicz Ph.D. Executive Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President - Clinical Development, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - Pharmaceutical Research
Age: 59
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 53
Bio & Compensation  - Reuters
John Northcott Vice President - Marketing, Commercial Strategy and Operations
Bio & Compensation  - Reuters
Philippe J. Amouyal Independent Director
Age: 54
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters